Indaptus Therapeutics (INDP) Competitors $0.38 -0.02 (-3.85%) Closing price 04:00 PM EasternExtended Trading$0.40 +0.02 (+4.21%) As of 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock INDP vs. SRZN, OKUR, GBIO, CVKD, DARE, BCAB, QNTM, CLNN, CARA, and GDTCShould you be buying Indaptus Therapeutics stock or one of its competitors? The main competitors of Indaptus Therapeutics include Surrozen (SRZN), OnKure Therapeutics (OKUR), Generation Bio (GBIO), Cadrenal Therapeutics (CVKD), Daré Bioscience (DARE), BioAtla (BCAB), Quantum Biopharma (QNTM), Clene (CLNN), Cara Therapeutics (CARA), and CytoMed Therapeutics (GDTC). These companies are all part of the "pharmaceutical products" industry. Indaptus Therapeutics vs. Surrozen OnKure Therapeutics Generation Bio Cadrenal Therapeutics Daré Bioscience BioAtla Quantum Biopharma Clene Cara Therapeutics CytoMed Therapeutics Indaptus Therapeutics (NASDAQ:INDP) and Surrozen (NASDAQ:SRZN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, community ranking, risk and dividends. Do insiders & institutionals have more ownership in INDP or SRZN? 7.1% of Indaptus Therapeutics shares are held by institutional investors. Comparatively, 66.6% of Surrozen shares are held by institutional investors. 29.5% of Indaptus Therapeutics shares are held by company insiders. Comparatively, 45.2% of Surrozen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community favor INDP or SRZN? Indaptus Therapeutics received 6 more outperform votes than Surrozen when rated by MarketBeat users. Likewise, 86.67% of users gave Indaptus Therapeutics an outperform vote while only 31.82% of users gave Surrozen an outperform vote. CompanyUnderperformOutperformIndaptus TherapeuticsOutperform Votes1386.67% Underperform Votes213.33%SurrozenOutperform Votes731.82% Underperform Votes1568.18% Which has more volatility and risk, INDP or SRZN? Indaptus Therapeutics has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500. Comparatively, Surrozen has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Is INDP or SRZN more profitable? Surrozen's return on equity of -120.51% beat Indaptus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Indaptus TherapeuticsN/A -177.27% -141.06% Surrozen N/A -120.51%-54.68% Does the media favor INDP or SRZN? In the previous week, Surrozen had 5 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 5 mentions for Surrozen and 0 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 1.50 beat Surrozen's score of -0.19 indicating that Indaptus Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Indaptus Therapeutics Very Positive Surrozen Neutral Do analysts rate INDP or SRZN? Indaptus Therapeutics currently has a consensus target price of $8.50, indicating a potential upside of 2,136.84%. Surrozen has a consensus target price of $38.50, indicating a potential upside of 426.68%. Given Indaptus Therapeutics' higher possible upside, research analysts clearly believe Indaptus Therapeutics is more favorable than Surrozen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indaptus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Surrozen 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better valuation & earnings, INDP or SRZN? Indaptus Therapeutics has higher earnings, but lower revenue than Surrozen. Surrozen is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIndaptus TherapeuticsN/AN/A-$15.42M-$1.49-0.26Surrozen$11.64M5.38-$43.04M-$24.96-0.29 SummaryIndaptus Therapeutics beats Surrozen on 8 of the 14 factors compared between the two stocks. Get Indaptus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INDP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INDP vs. The Competition Export to ExcelMetricIndaptus TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.09M$6.52B$5.37B$8.38BDividend YieldN/A2.65%5.22%4.11%P/E Ratio-0.228.9226.8419.71Price / SalesN/A253.80392.34117.39Price / CashN/A65.8538.2534.62Price / Book0.266.466.794.50Net Income-$15.42M$143.98M$3.23B$248.18M7 Day Performance-10.29%3.04%4.07%1.14%1 Month Performance-18.26%7.44%12.52%15.20%1 Year Performance-83.83%-2.46%16.83%6.56% Indaptus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INDPIndaptus Therapeutics3.3477 of 5 stars$0.38-3.8%$8.50+2,136.8%-83.1%$6.09MN/A-0.226Earnings ReportGap DownSRZNSurrozen3.0023 of 5 stars$8.00-4.2%$38.50+381.3%-10.5%$26.25M$10.66M-0.3280Gap DownOKUROnKure Therapeutics2.9352 of 5 stars$1.95+1.6%$32.33+1,558.1%N/A$26.20MN/A-0.16N/ANews CoverageInsider TradeGap UpGBIOGeneration Bio3.2679 of 5 stars$0.39+8.4%$7.33+1,778.4%-88.6%$26.16M$19.89M-0.18150Gap UpHigh Trading VolumeCVKDCadrenal Therapeutics2.5258 of 5 stars$13.38-7.4%$32.00+139.2%N/A$25.96MN/A-2.004News CoverageDAREDaré Bioscience1.4085 of 5 stars$2.88-1.0%$24.00+733.3%-60.5%$25.49M$9,784.00-4.8830BCABBioAtla2.0062 of 5 stars$0.43+0.6%$6.00+1,288.2%-84.0%$25.24M$11M-0.2560Gap UpQNTMQuantum BiopharmaN/A$9.12+0.6%N/AN/A$24.68MN/A-0.59N/ANews CoverageEarnings ReportCLNNClene2.5375 of 5 stars$2.72+3.4%$40.00+1,370.6%-65.1%$24.43M$342,000.00-0.52100CARACara Therapeutics1.2352 of 5 starsN/A$83.52+∞N/A$24.33M$7.14M-0.2580Gap DownHigh Trading VolumeGDTCCytoMed Therapeutics1.5888 of 5 stars$2.30+3.8%$5.00+117.0%-1.0%$24.29M$69,501.000.00N/AGap Up Related Companies and Tools Related Companies SRZN Alternatives OKUR Alternatives GBIO Alternatives CVKD Alternatives DARE Alternatives BCAB Alternatives QNTM Alternatives CLNN Alternatives CARA Alternatives GDTC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INDP) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Indaptus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Indaptus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
